Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report
- PMID: 16937543
- PMCID: PMC4088030
- DOI: 10.3748/wjg.v12.i32.5244
Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report
Abstract
Assigning causality in drug-induced liver injury is challenging particularly when more than one drug could be responsible. We report a woman on long-term therapy with raloxifen who developed acute cholestasis shortly after starting fenofibrate. The picture evolved into chronic cholestasis. We hypothesized that an interaction at the metabolic level could have triggered the presentation of hepatotoxicity after a very short time of exposure to fenofibrate in this patient. The findings of an overexpression of vascular endothelial growth factor in the liver biopsy suggest that angiogenesis might play a role in the persistence of toxic cholestasis.
Figures
References
-
- Ganne-Carrié N, de Leusse A, Guettier C, Castera L, Levecq H, Bertrand HJ, Plumet Y, Trinchet JC, Beaugrand M. [Autoimmune hepatitis induced by fibrates] Gastroenterol Clin Biol. 1998;22:525–529. - PubMed
-
- Lepicard A, Mallat A, Zafrani ES, Dhumeaux D. [Chronic lesion of the interlobular bile ducts induced by fenofibrate] Gastroenterol Clin Biol. 1994;18:1033–1035. - PubMed
-
- Vilches AR, Pérez V, Suchecki DE. Raloxifene-associated hepatitis. Lancet. 1998;352:1524–1525. - PubMed
-
- Vicioso L, Gonzalez FJ, Alvarez M, Ribelles N, Molina M, Marquez A, Perez L, Matilla A, Alba E. Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer. Am J Clin Pathol. 2006;125:111–118. - PubMed
-
- Larsson A, Sköldenberg E, Ericson H. Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis. 2002;5:107–110. - PubMed
